Hypothesis: What is the Best We Can Do with Hydroxychloroquine for COVID-19?

References

• Gates B. Responding to Covid-19 - a once-in-a-century pandemic? N Engl J Med. 2020;382(18):1677–1679. doi:10.1056/NEJMp200376232109012
   PubMed Web of Science ®Google Scholar
• COVID-19 CORONAVIRUS PANDEMIC. https://www.worldometers.info/coronavirus/. Accessed October 9, 2020.
   Google Scholar
• Peto J, Alwan NA, Godfrey KM, et al. Universal weekly testing as the UK COVID-19 lockdown exit strategy. Lancet. 2020;395(10234):1420–1421. doi:10.1016/S0140-6736(20)30936-332325027
   PubMed Web of Science ®Google Scholar
• Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science. 2020;368(6493):860–868. doi:10.1126/science.abb579332291278
   PubMed Web of Science ®Google Scholar
• Ahsan W, Javed S, Bratty MA, Alhazmi HA, Najmi A. Treatment of SARS-CoV-2: how far have we reached? Drug Discov Ther. 2020;14(2):67–72. doi:10.5582/ddt.2020.0300832336723
   PubMed Web of Science ®Google Scholar
• Clinical trials on Covid19. Available from: https://www.clinicaltrials.gov/ct2/results?cond=Covid19&term=&cntry=&state=&city=&dist=. Accessed October 9, 2020.
   Google Scholar
• Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect Dis. 2006;6(2):67–69. doi:10.1016/S1473-3099(06)70361-916439323
   PubMed Web of Science ®Google Scholar
• Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16. doi:10.1038/s41421-020-0156-032194981
   PubMed Web of Science ®Google Scholar
• Sun X, Ni Y, Zhang M. Rheumotologitsts’ view on the use of hydroxychloroquine to treat COVID-19. Emerg Microbes Infect. 2020;9(1):830–832. doi:10.1080/22221751.2020.176014532338155
   PubMed Web of Science ®Google Scholar
• Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382(25):2411–2418. doi:10.1056/NEJMoa201241032379955
   PubMed Web of Science ®Google Scholar
• Huang M, Li M, Xiao F, et al. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. Natl Sci Rev. 2020;7(9):1428–1436. doi:10.1093/nsr/nwaa113
   PubMed Web of Science ®Google Scholar
• Mehra MR, Ruschitzka F, Patel AN. Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;395(10240):1820. doi:10.1016/S0140-6736(20)31324-632511943
   PubMed Web of Science ®Google Scholar
• Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020;323(24):2493–2502. doi:10.1001/jama.2020.863032392282
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. doi:10.1038/s41422-020-0282-032020029
   PubMed Web of Science ®Google Scholar
• Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM. Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review. Ann Intern Med. 2020.
   Web of Science ®Google Scholar
• Lagier JC, Million M, Gautret P, et al. Outcomes of 3737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis. Travel Med Infect Dis. 2020;36:101791. doi:10.1016/j.tmaid.2020.10179132593867
   PubMed Web of Science ®Google Scholar
• Risch HA. Early outpatient treatment of symptomatic, high-risk Covid-19 patients that should be ramped-up immediately as key to the pandemic crisis. Am J Epidemiol. 2020.
   Web of Science ®Google Scholar
• Zhou D, Dai SM, Tong Q. COVID-19 a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020;75(7):1667–1670. doi:10.1093/jac/dkaa11432196083
   PubMed Web of Science ®Google Scholar
• Fantini J, Di Scala C, Chahinian H, Yahi N. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents. 2020;55(5):105960. doi:10.1016/j.ijantimicag.2020.10596032251731
   PubMed Web of Science ®Google Scholar
• Podsiadlo P, Komiyama T, Fuller RS, Blum O. Furin inhibition by compounds of copper and zinc. J Biol Chem. 2004;279(35):36219–36227. doi:10.1074/jbc.M40033820015140896
   PubMed Web of Science ®Google Scholar
• Johnson BA, Xie X, Kalveram B, et al. Furin cleavage site is key to SARS-CoV-2 pathogenesis. bioRxiv. 2020.
   Google Scholar
• Shittu MO, Afolami OI. Improving the efficacy of Chloroquine and Hydroxychloroquine against SARS-CoV-2 may require Zinc additives - a better synergy for future COVID-19 clinical trials. Infez Med. 2020;28(2):192–197.32335560
   PubMedGoogle Scholar
• Te Velthuis AJW, van den Worm SHE, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn2+ INHIBITS CORONAVIRUS AND ARTERIVIRUS RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog. 2010;6(11):e1001176. doi:10.1371/journal.ppat.100117621079686
   PubMed Web of Science ®Google Scholar
• Carlucci P, Ahuja T, Petrilli CM, Rajagopalan H, Jones S, Rahimian J. Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients. medRxiv. 2020:2020.2005.2002.20080036.
   Google Scholar
• Xiao L, Sakagami H, Miwa N. ACE2: the key molecule for understanding the pathophysiology of severe and critical conditions of COVID-19: demon or angel? Viruses. 2020;12:5. doi:10.3390/v12050491
   Web of Science ®Google Scholar
• Puelles VG, Lütgehetmann M, Lindenmeyer MT, et al. Multiorgan and Renal Tropism of SARS-CoV-2. N Engl J Med. 2020;383(6):590–592. doi:10.1056/NEJMc201140032402155
   PubMed Web of Science ®Google Scholar
• Butowt R, Bilinska K. SARS-CoV-2: olfaction, brain infection, and the urgent need for clinical samples allowing earlier virus detection. ACS Chem Neurosci. 2020;11(9):1200–1203. doi:10.1021/acschemneuro.0c0017232283006
   PubMed Web of Science ®Google Scholar
• Lenzer J. Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence. BMJ. 2020;369:m1335. doi:10.1136/bmj.m133532238355
   PubMed Web of Science ®Google Scholar
• COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes. Available from: https://www.ema.europa.eu/en/documents/press-release/covid-19-chloroquine-hydroxychloroquine-only-be-used-clinical-trials-emergency-use-programmes_en.pdf. Accessed October 9, 2020.
   Google Scholar
• Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States Veterans Hospitalized with COVID-19. Med (N Y). 2020.
   Google Scholar
• Prodromos CC. Hydroxychloroquine is protective to the heart, not Harmful: a systematic review. New Microbes New Infect. 2020;100747. doi:10.1016/j.nmni.2020.10074732839670
   PubMed Web of Science ®Google Scholar
• Even those with “mild” symptoms can suffer from Covid-19 for a long time. Available from: https://www.vrt.be/vrtnws/en/2020/06/19/even-those-wild-mild-symptoms-can-suffer-from-covid-19-for-a-lon/. 2020 Accessed October 9, 2020.
   Google Scholar
• Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020;382(22):2081–2090.32329971
   PubMed Web of Science ®Google Scholar
• Gandhi M, Yokoe DS, Havlir DV. Asymptomatic transmission. The achilles’ heel of current strategies to control Covid-19. N Engl J Med. 2020;382(22):2158–2160. doi:10.1056/NEJMe200975832329972
   PubMed Web of Science ®Google Scholar
• Lee SH, Son H, Peck KR. Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals? Int J Antimicrob Agents. 2020;105988.
   Google Scholar
• Jakhar D, Kaur I. Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus. Nat Med. 2020;26(5):632. doi:10.1038/s41591-020-0853-0
   PubMed Web of Science ®Google Scholar
• Chorin E, Dai M, Shulman E, et al. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med. 2020;26(6):808–809. doi:10.1038/s41591-020-0888-232488217
   PubMed Web of Science ®Google Scholar
• Sacher F, Fauchier L, Boveda S, et al. Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection. Arch Cardiovasc Dis. 2020;113(5):293–296. doi:10.1016/j.acvd.2020.04.00332354666
   PubMed Web of Science ®Google Scholar
• Hoffman T, Nissen K, Krambrich J, et al. Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2. Infect Ecol Epidemiol. 2020;10(1):1754538.32363011
   PubMedGoogle Scholar
• Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584(7821):457–462. doi:10.1038/s41586-020-2550-z32668444
   PubMed Web of Science ®Google Scholar
• Wu F, Wang A, Liu M, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv. 2020:2020.2003.2030.20047365.
   Google Scholar
• Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell.
   Web of Science ®Google Scholar
• Wilson N, Kvalsvig A, Barnard LT, Baker M. Case-fatality risk estimates for COVID-19 calculated by using a lag time for fatality. Emergi Infect Dis J. 2020;26(6):1339. doi:10.3201/eid2606.200320
   PubMed Web of Science ®Google Scholar